DE60015726T2 - Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben - Google Patents
Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben Download PDFInfo
- Publication number
- DE60015726T2 DE60015726T2 DE60015726T DE60015726T DE60015726T2 DE 60015726 T2 DE60015726 T2 DE 60015726T2 DE 60015726 T DE60015726 T DE 60015726T DE 60015726 T DE60015726 T DE 60015726T DE 60015726 T2 DE60015726 T2 DE 60015726T2
- Authority
- DE
- Germany
- Prior art keywords
- time
- profile
- sample
- slope
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 73
- 239000013610 patient sample Substances 0.000 title claims description 8
- 229940030225 antihemorrhagics Drugs 0.000 title abstract description 10
- 230000000025 haemostatic effect Effects 0.000 title abstract description 10
- 230000035602 clotting Effects 0.000 claims abstract description 61
- 238000005259 measurement Methods 0.000 claims abstract description 45
- 230000036962 time dependent Effects 0.000 claims abstract description 43
- 230000004064 dysfunction Effects 0.000 claims abstract description 13
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 83
- 239000000523 sample Substances 0.000 claims description 73
- 238000012360 testing method Methods 0.000 claims description 62
- 230000003287 optical effect Effects 0.000 claims description 61
- 230000005540 biological transmission Effects 0.000 claims description 48
- 238000004458 analytical method Methods 0.000 claims description 43
- 102000008946 Fibrinogen Human genes 0.000 claims description 42
- 108010049003 Fibrinogen Proteins 0.000 claims description 42
- 229940012952 fibrinogen Drugs 0.000 claims description 42
- 206010053567 Coagulopathies Diseases 0.000 claims description 33
- 230000035945 sensitivity Effects 0.000 claims description 31
- 230000006881 hemostatic dysfunction Effects 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 239000003154 D dimer Substances 0.000 claims description 11
- 108010052295 fibrin fragment D Proteins 0.000 claims description 11
- 208000007536 Thrombosis Diseases 0.000 claims description 9
- 206010010356 Congenital anomaly Diseases 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 230000002439 hemostatic effect Effects 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 238000004364 calculation method Methods 0.000 claims description 3
- 230000000875 corresponding effect Effects 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 230000031915 positive regulation of coagulation Effects 0.000 claims description 3
- DWHCYDWXLJOFFO-UHFFFAOYSA-N 4-(5-phenylthiophen-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(C=2C=CC=CC=2)S1 DWHCYDWXLJOFFO-UHFFFAOYSA-N 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 238000013168 hemostasis test Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000010444 Acidosis Diseases 0.000 claims 1
- 206010002886 Aortic aneurysm rupture Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000007950 acidosis Effects 0.000 claims 1
- 208000026545 acidosis disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 230000007257 malfunction Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002051 biphasic effect Effects 0.000 abstract description 47
- 108010094028 Prothrombin Proteins 0.000 description 94
- 102100027378 Prothrombin Human genes 0.000 description 94
- 229940039716 prothrombin Drugs 0.000 description 94
- 238000013528 artificial neural network Methods 0.000 description 51
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 50
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 50
- 239000003114 blood coagulation factor Substances 0.000 description 50
- 238000012549 training Methods 0.000 description 50
- 238000005345 coagulation Methods 0.000 description 48
- 230000015271 coagulation Effects 0.000 description 43
- 230000007812 deficiency Effects 0.000 description 38
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 36
- 229960002897 heparin Drugs 0.000 description 36
- 229920000669 heparin Polymers 0.000 description 36
- 239000013598 vector Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 210000002569 neuron Anatomy 0.000 description 18
- 230000005856 abnormality Effects 0.000 description 16
- 239000003146 anticoagulant agent Substances 0.000 description 16
- 230000002159 abnormal effect Effects 0.000 description 15
- 238000004422 calculation algorithm Methods 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 15
- 229940127219 anticoagulant drug Drugs 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 13
- 230000002950 deficient Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 102100026735 Coagulation factor VIII Human genes 0.000 description 10
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000023597 hemostasis Effects 0.000 description 10
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 8
- 210000000225 synapse Anatomy 0.000 description 8
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 7
- 108090000935 Antithrombin III Proteins 0.000 description 7
- 108010000499 Thromboplastin Proteins 0.000 description 7
- 102000002262 Thromboplastin Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000001994 activation Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 101800004937 Protein C Proteins 0.000 description 6
- 102000017975 Protein C Human genes 0.000 description 6
- 101800001700 Saposin-D Proteins 0.000 description 6
- 108090000190 Thrombin Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 210000004205 output neuron Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229960000856 protein c Drugs 0.000 description 6
- 238000013139 quantization Methods 0.000 description 6
- 229960004072 thrombin Drugs 0.000 description 6
- 102100022977 Antithrombin-III Human genes 0.000 description 5
- 108010054218 Factor VIII Proteins 0.000 description 5
- 102000001690 Factor VIII Human genes 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 229940105778 coagulation factor viii Drugs 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 229940096437 Protein S Drugs 0.000 description 4
- 102000029301 Protein S Human genes 0.000 description 4
- 108010066124 Protein S Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 102100029117 Coagulation factor X Human genes 0.000 description 3
- 108010014173 Factor X Proteins 0.000 description 3
- 108010090444 Innovin Proteins 0.000 description 3
- 229940105756 coagulation factor x Drugs 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012106 screening analysis Methods 0.000 description 3
- 208000013223 septicemia Diseases 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- -1 APTT Proteins 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 208000014763 coagulation protein disease Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000010365 information processing Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000013178 mathematical model Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 101100129500 Caenorhabditis elegans max-2 gene Proteins 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- GJAARPKBDFKHFS-UHFFFAOYSA-N Gerin Natural products COC(=O)C(=C)C1CC2C(=C)C(=O)C=CC2(C)CC1OC(=O)C GJAARPKBDFKHFS-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001152 differential interference contrast microscopy Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 239000000282 fibrinogen degradation product Substances 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000011478 gradient descent method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000002364 input neuron Anatomy 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4905—Determining clotting time of blood
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24434099A | 1999-02-04 | 1999-02-04 | |
| US244340 | 1999-02-04 | ||
| PCT/US2000/002987 WO2000046603A1 (en) | 1999-02-04 | 2000-02-04 | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60015726D1 DE60015726D1 (de) | 2004-12-16 |
| DE60015726T2 true DE60015726T2 (de) | 2005-12-22 |
Family
ID=22922329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60015726T Expired - Lifetime DE60015726T2 (de) | 1999-02-04 | 2000-02-04 | Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7211438B2 (enExample) |
| EP (1) | EP1147423B1 (enExample) |
| JP (1) | JP4486260B2 (enExample) |
| AT (1) | ATE282208T1 (enExample) |
| AU (1) | AU774889B2 (enExample) |
| CA (1) | CA2362055C (enExample) |
| DE (1) | DE60015726T2 (enExample) |
| ES (1) | ES2231167T3 (enExample) |
| WO (1) | WO2000046603A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732213B2 (en) * | 1999-02-22 | 2010-06-08 | Coramed Healthcare, Inc. | Method of evaluating patient hemostasis |
| US6743596B1 (en) * | 2000-10-27 | 2004-06-01 | Biomerieux, Inc. | Method of determining global coagulability hemostatic potential |
| EP1476752A4 (en) * | 2002-02-27 | 2008-02-13 | Bio Merieux Inc | METHOD FOR DIAGNOSING AND MONITORING HEMOSTATIC DYSFUNCTION, SEVERE INFECTION AND SYSTEMATIC INFLAMMATORY RESPONSE SYNDROME |
| MXPA05005031A (es) | 2002-11-12 | 2005-11-17 | Becton Dickinson Co | Diagnostico de la sepsis o sirs usando perfiles de biomarcadores. |
| CA2505843A1 (en) | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
| WO2005038690A2 (en) * | 2003-10-21 | 2005-04-28 | Philips Intellectual Property & Standards Gmbh | Method of automatically displaying medical measurement data |
| EP1869463A4 (en) | 2005-04-15 | 2010-05-05 | Becton Dickinson Co | SEPSIS DIAGNOSIS |
| US7480593B2 (en) * | 2005-08-03 | 2009-01-20 | Suresh Gopalan | Methods and systems for high confidence utilization of datasets |
| CN101946169B (zh) * | 2008-02-14 | 2013-06-12 | 欧雷恩诊断公司 | 用于预测未来特性的方法 |
| US8669113B2 (en) | 2008-04-03 | 2014-03-11 | Becton, Dickinson And Company | Advanced detection of sepsis |
| WO2011159820A1 (en) * | 2010-06-15 | 2011-12-22 | Bayer Healthcare Llc | Device |
| CN104285148B (zh) * | 2012-05-07 | 2016-10-12 | 美迪恩斯生命科技株式会社 | 检测弥散性血管内凝血或感染性弥散性血管内凝血的方法 |
| WO2014030162A1 (en) * | 2012-08-22 | 2014-02-27 | Ben-Gurion University Of The Negev Research & Development Authority | Separating clinically relevant sources of electrical activity in ecg signals |
| US10823743B1 (en) | 2013-10-28 | 2020-11-03 | Ifirst Medical Technologies, Inc. | Methods of measuring coagulation of a biological sample |
| JP6430809B2 (ja) * | 2014-12-19 | 2018-11-28 | 公立大学法人奈良県立医科大学 | 血液検体を判定するための方法、システム及びコンピュータプログラム、並びに血液検体分析装置 |
| WO2018063914A1 (en) | 2016-09-29 | 2018-04-05 | Animantis, Llc | Methods and apparatus for assessing immune system activity and therapeutic efficacy |
| ES2982234T3 (es) * | 2017-05-15 | 2024-10-15 | Medial Res Ltd | Sistemas y procedimientos para la agregación de resultados de pruebas de laboratorio generados automáticamente |
| US12277814B2 (en) | 2020-01-29 | 2025-04-15 | Ifirst Medical Technologies, Inc. | Medical analyzer and diagnostic sample profiler |
| GB202004047D0 (en) | 2020-03-20 | 2020-05-06 | Ainger Phill | Point of care sepsis assay device and method |
| EP4212880A4 (en) * | 2020-09-08 | 2024-10-23 | Sekisui Medical Co., Ltd. | BLOOD COAGULATION REACTION ANALYSIS METHOD |
| JP7594404B2 (ja) * | 2020-10-09 | 2024-12-04 | シスメックス株式会社 | 血液検体の分析方法、分析装置、および分析プログラム |
| CN116472354A (zh) * | 2020-10-29 | 2023-07-21 | 积水医疗株式会社 | 凝血反应的检测方法 |
| CN116917739A (zh) * | 2021-03-05 | 2023-10-20 | 积水医疗株式会社 | 凝固时间延长因素的推断方法 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US177089A (en) * | 1876-05-09 | Improvement in bit-stocks | ||
| US590665A (en) * | 1897-09-28 | Machine | ||
| US1691741A (en) * | 1928-11-13 | Carrying bag and handle therefor | ||
| US1076086A (en) * | 1910-10-21 | 1913-10-21 | Charles C Vosburgh | Window-furnishing. |
| US2070327A (en) * | 1931-06-08 | 1937-02-09 | Wood Newspaper Mach Corp | Paper roll braking mechanism |
| US2005014A (en) * | 1932-04-19 | 1935-06-18 | Warner Brothers Pictures Inc | Focusing device for a motion picture camera |
| US2012877A (en) * | 1932-11-03 | 1935-08-27 | Iwasa Morizo | Hearing appliance |
| US2061953A (en) * | 1936-02-12 | 1936-11-24 | Sampson Max | Toy aeroplane and control therefor |
| US2364453A (en) * | 1939-09-13 | 1944-12-05 | Standard Oil Co | Processing hydrocarbon distillates |
| US2635081A (en) * | 1950-12-13 | 1953-04-14 | Sun Oil Co | Molybdenum disulfide on a spent cracking catalyst |
| US3307392A (en) | 1964-05-04 | 1967-03-07 | Research Corp | Automatic prothrombin timer apparatus and method |
| US3458287A (en) | 1965-04-29 | 1969-07-29 | Medical Laboratory Automation | Method and means of determining endpoint times in blood clotting tests |
| US3502878A (en) * | 1967-09-22 | 1970-03-24 | Us Health Education & Welfare | Automatic x-ray apparatus for limiting the field size of a projected x-ray beam in response to film size and to source-to-film distance |
| US3658480A (en) | 1970-04-13 | 1972-04-25 | Bio Data Corp | Coagulation timing apparatus, and method |
| US4047890A (en) | 1973-11-01 | 1977-09-13 | Bio/Data Corporation | Method and apparatus for determining deficiencies in enzymatic reactors particularly clotting factor levels in blood plasmas |
| SU590665A1 (ru) | 1976-02-11 | 1978-01-30 | Новосибирский государственный медицинский институт | Способ исследовани процесса свертывани крови |
| US4040788A (en) | 1976-04-05 | 1977-08-09 | Sanford L. Simons | Apparatus, instrumentation, and method for comparing samples |
| DE2635081C3 (de) | 1976-08-04 | 1980-08-07 | Bio/Data Corp., Willow Grove, Pa. (V.St.A.) | Verfahren und Vorrichtung zur Bestimmung von Blutplasma-Gerinnungsfaktorpegeln |
| FR2364453A1 (fr) | 1976-09-08 | 1978-04-07 | Lacombe Pierre | Dispositif electronique apportant un perfectionnement aux appareils destines a analyser la coagulation sanguine : prothrombinometre citrate-oxalate |
| US4199748A (en) | 1976-11-01 | 1980-04-22 | Rush-Presbyterian-St. Luke's Medical Center | Automated method and apparatus for classification of cells with application to the diagnosis of anemia |
| JPS5451893A (en) | 1977-09-30 | 1979-04-24 | Sankyo Co | Measuring of blood coagulating time |
| JPS5822703B2 (ja) | 1978-08-30 | 1983-05-10 | 三共株式会社 | 血液凝固測定方法 |
| US4254760A (en) * | 1978-09-22 | 1981-03-10 | Sirimarco Robert A | Ceramic heat absorption panel |
| US4289498A (en) | 1979-01-08 | 1981-09-15 | Ortho Diagnostics, Inc. | One-stage prothrombin assay and compositions useful therein |
| US4766083A (en) | 1982-04-04 | 1988-08-23 | Wako Pure Chemical Industries, Ltd. | Method for the photometric determination of biological agglutination |
| SU1076086A1 (ru) | 1982-12-28 | 1984-02-29 | Всесоюзный Научно-Исследовательский И Конструкторский Институт Медицинской Лабораторной Техники | Гемокоагулограф |
| US4705756A (en) | 1983-01-26 | 1987-11-10 | University Of Medicine And Dentistry Of New Jersey | Method of determining the existence and/or the monitoring of a pathological condition in a mammal |
| EP0115459A3 (en) | 1983-01-26 | 1986-11-20 | University Of Medicine And Dentistry Of New Jersey | Hematological prediction of sepsis and other disease states |
| JPS59203959A (ja) | 1983-05-04 | 1984-11-19 | Toa Medical Electronics Co Ltd | 血液凝固時間測定装置 |
| JPH0695095B2 (ja) | 1983-11-25 | 1994-11-24 | 株式会社島津製作所 | 全自動血液分析装置 |
| DE3502878A1 (de) | 1985-01-29 | 1986-07-31 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur bestimmung des fibrinolytischen zustands von plasma |
| JPS61272655A (ja) | 1985-05-28 | 1986-12-02 | Iryo Kogaku Kenkyusho:Kk | 血小板凝集能の定量的判定方法 |
| GB8516081D0 (en) | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
| US4902630A (en) | 1985-07-22 | 1990-02-20 | Abbott Laboratories | Fluorescence polarization immunoassy and reagents for measurement of c-reactive protein |
| AU633488B2 (en) | 1988-04-04 | 1993-02-04 | Northwestern University | Binding of immune complexes by modified forms of c-reactive protein |
| US5593897A (en) | 1988-04-04 | 1997-01-14 | Northwestern University | Binding of immune complexes by modified forms of C-reactive protein |
| US4965725B1 (en) | 1988-04-08 | 1996-05-07 | Neuromedical Systems Inc | Neural network based automated cytological specimen classification system and method |
| US5156974A (en) | 1988-05-27 | 1992-10-20 | Biodata Corporation | Method for determining the fibrinogen level of a blood sample |
| US5003065A (en) | 1988-06-14 | 1991-03-26 | Carey Merritt | Compounds and process for measuring c-reactive protein |
| US5697369A (en) | 1988-12-22 | 1997-12-16 | Biofield Corp. | Method and apparatus for disease, injury and bodily condition screening or sensing |
| US5055412A (en) | 1989-03-21 | 1991-10-08 | Proksch Gary J | Factor sensitive reagent for testing of blood coagulation containing ellagic acid and divalent metal ions and method of making the same |
| US5500345A (en) | 1989-04-25 | 1996-03-19 | Iatron Laboratories, Inc. | Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein |
| JPH04505857A (ja) | 1989-06-27 | 1992-10-15 | ラッシュ―プレズビティリアン―セント ルークス メディカル センター | Ｃ反応性蛋白質に対するモノクローナル抗体 |
| WO1991001383A1 (en) | 1989-07-14 | 1991-02-07 | Michigan State University | Method for diagnosing blood clotting disorders |
| US5051357A (en) | 1989-07-14 | 1991-09-24 | Board Of Trustees Operating Michigan State University | Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor |
| JP3055933B2 (ja) | 1989-07-20 | 2000-06-26 | アナリティカル・コントロール・システムズ・インコーポレーテッド | 改良された安定な凝固対照 |
| SU1691741A1 (ru) | 1989-08-25 | 1991-11-15 | Донецкий государственный медицинский институт | Способ прогнозировани геморрагических осложнений при травматической болезни |
| US4998535A (en) | 1989-09-05 | 1991-03-12 | Univ. of Washington New England Medical Center Hospitals, Inc. | Thrombolysis predictive instrument |
| US5262303A (en) | 1989-10-13 | 1993-11-16 | Trustees Of Boston University | Ligand/anti-ligand assays for adherent proteins |
| US5646046A (en) | 1989-12-01 | 1997-07-08 | Akzo Nobel N.V. | Method and instrument for automatically performing analysis relating to thrombosis and hemostasis |
| IE904244A1 (en) | 1989-12-01 | 1991-06-05 | Akzo Nv | Direct fibrinogen assay |
| US5169786A (en) | 1989-12-19 | 1992-12-08 | Ortho Diagnostic Systems, Inc. | Method of determining levels of extrinsic and intrinsic clotting factors and protein c |
| ATE140034T1 (de) | 1990-04-17 | 1996-07-15 | Analytical Control Syst Inc | Koagulationsassays und reagenzien |
| US5862304A (en) | 1990-05-21 | 1999-01-19 | Board Of Regents, The University Of Texas System | Method for predicting the future occurrence of clinically occult or non-existent medical conditions |
| US5218529A (en) | 1990-07-30 | 1993-06-08 | University Of Georgia Research Foundation, Inc. | Neural network system and methods for analysis of organic materials and structures using spectral data |
| JPH04254760A (ja) | 1991-01-30 | 1992-09-10 | Eiken Chem Co Ltd | 血清アミロイドａ標準物質、およびその設定方法 |
| US5221628A (en) | 1991-03-19 | 1993-06-22 | Northwestern University | Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component |
| RU2012877C1 (ru) | 1991-04-01 | 1994-05-15 | Белорусский научно-исследовательский институт охраны материнства и детства | Способ прогнозирования синдрома дыхательных расстройств у недоношенных новорожденных |
| US5180835A (en) * | 1991-06-25 | 1993-01-19 | American Cyanamid Company | Process for the preparation of monomeric tetramethoxymethylglycoloril |
| ES2094212T3 (es) | 1991-08-02 | 1997-01-16 | Grifols Grupo Sa | Procedimiento y aparato para la determinacion del tiempo de coagulacion de la sangre y del plasma. |
| WO1993007491A1 (en) | 1991-10-04 | 1993-04-15 | Board Of Regents Of The University Of Nebraska | A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins |
| US5716795A (en) | 1991-10-04 | 1998-02-10 | Matschiner; John T. | Thrombomodulin-based coagulometric assay of the protein C system |
| JP3222135B2 (ja) | 1991-11-04 | 2001-10-22 | アデザ バイオメディカル コーポレイション | 早期分娩の危険が増大している女性を特定するスクリーニング方法 |
| JPH05180835A (ja) | 1991-12-27 | 1993-07-23 | S R L:Kk | ループスアンチコアグラントの測定方法 |
| US5318958A (en) | 1992-05-29 | 1994-06-07 | Queen's University At Kingston | Amyloid precursor protein |
| JP2934557B2 (ja) | 1992-07-10 | 1999-08-16 | 国際試薬株式会社 | 血液凝固時間測定方法とその装置 |
| JPH0636061A (ja) | 1992-07-21 | 1994-02-10 | Fujitsu Ltd | 階層型ニューラルネットワークの学習方式 |
| US5388164A (en) | 1992-08-19 | 1995-02-07 | Olympus Optical Co., Ltd. | Method for judging particle agglutination patterns using neural networks |
| JP3224607B2 (ja) | 1992-09-11 | 2001-11-05 | 株式会社アズウェル | 血液凝固第ｘｉｉｉ因子活性測定方法および該測定用試薬キット |
| US5369484A (en) | 1992-11-09 | 1994-11-29 | Akzo N.V. | Multiple discrete analyzer test apparatus and method |
| US5358852A (en) | 1992-12-21 | 1994-10-25 | Eastman Kodak Company | Use of calcium in immunoassay for measurement of C-reactive protein |
| RU2070327C1 (ru) | 1992-12-25 | 1996-12-10 | Безруков Александр Васильевич | Устройство для измерения времени свертывания крови |
| US5344754A (en) | 1993-01-13 | 1994-09-06 | Avocet Medical, Inc. | Assay timed by electrical resistance change and test strip |
| JP2938302B2 (ja) | 1993-02-25 | 1999-08-23 | 国際試薬株式会社 | 血液凝固時間測定方法とその装置 |
| JPH06249857A (ja) | 1993-02-26 | 1994-09-09 | Hitachi Ltd | 自動分析装置 |
| RU2061953C1 (ru) | 1993-03-10 | 1996-06-10 | Тюменский государственный медицинский институт МЗ РФ | Способ количественного определения общей коагуляционной активности тромбоцитов |
| US5670329A (en) | 1993-05-28 | 1997-09-23 | Cardiovascular Diagnostics, Inc. | Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field |
| DK0633473T3 (da) | 1993-06-30 | 1999-08-09 | Stiftung F R Diagnostische For | Måling af den aktiverede partielle thromboplastin-tid (APTT) i en reaktion i et enkelt trin |
| DE69434128T2 (de) | 1993-08-16 | 2005-11-10 | Biomerieux, Inc. | Methode und gerät zur automatischen durchführung von analysen bezüglich thrombose und blutgerinnung |
| US5526111A (en) | 1993-08-31 | 1996-06-11 | Boehringer Mannheim Corporation | Method and apparatus for calculating a coagulation characteristic of a sample of blood a blood fraction or a control |
| US5472852A (en) | 1993-09-15 | 1995-12-05 | Oklahoma Medical Research Foundation | Assay for detection of selective Protein C inhibition by patients |
| US5473732A (en) | 1993-11-02 | 1995-12-05 | Chang; Hou-Mei H. | Relational artificial intelligence system |
| US5553616A (en) | 1993-11-30 | 1996-09-10 | Florida Institute Of Technology | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator |
| US5856114A (en) | 1994-03-21 | 1999-01-05 | The University Of Vermont | Immunologic detection of factor VA fragments in hemorrhagic and thrombotic clinical settings |
| JPH08512139A (ja) | 1994-04-28 | 1996-12-17 | デイド、インターナショナル、インコーポレイテッド | プロトロンビン時間（ｐｔ）アッセイ用のキャリブレーター |
| WO1996006624A1 (en) | 1994-08-26 | 1996-03-07 | Immtech International, Inc. | A mutant protein and methods and materials for making and using it |
| US5504011A (en) | 1994-10-21 | 1996-04-02 | International Technidyne Corporation | Portable test apparatus and associated method of performing a blood coagulation test |
| SE9403833D0 (sv) | 1994-11-08 | 1994-11-08 | Global Hemostasis Inst Mgr Ab | Analysförfarande och kit |
| US5705395A (en) | 1994-11-14 | 1998-01-06 | The Scripps Research Institute | Method for diagnosis of thrombotic disorders |
| US5567596A (en) | 1994-12-29 | 1996-10-22 | Research Foundation Of State University Of New York | Rapid assay of activators and inhibitors of clotting |
| AU4634896A (en) | 1995-01-10 | 1996-07-31 | Hendrik Coenraad Hemker | Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods |
| US5708591A (en) | 1995-02-14 | 1998-01-13 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions |
| US6321164B1 (en) * | 1995-06-07 | 2001-11-20 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade |
| US6429017B1 (en) * | 1999-02-04 | 2002-08-06 | Biomerieux | Method for predicting the presence of haemostatic dysfunction in a patient sample |
| US6898532B1 (en) * | 1995-06-07 | 2005-05-24 | Biomerieux, Inc. | Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
| US5780255A (en) | 1995-06-09 | 1998-07-14 | Instrumentation Laboratory, S.P.A. | Protein C pathway screening test |
| US6194163B1 (en) | 1995-07-21 | 2001-02-27 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Method for the quantitative measurement of human acute phase serum amyloid A protein; recombinant protein; specific antibody |
| US5766869A (en) | 1995-11-30 | 1998-06-16 | Ahs Hospital Corp. | Factor V ratio blood test for susceptibility to thromboembolism |
| AU717559B2 (en) | 1996-03-22 | 2000-03-30 | Dade Behring Inc. | Combination reagent holding and test device |
| JPH1026621A (ja) | 1996-07-12 | 1998-01-27 | Dai Ichi Pure Chem Co Ltd | イムノアッセイ法 |
| US5684007A (en) | 1996-09-05 | 1997-11-04 | Otsuka Pharmaceutical Co., Ltd. | Methods for inhibiting cardiac fibroblast growth and cardiac fibrosis |
| JP3876022B2 (ja) | 1996-09-26 | 2007-01-31 | 生化学工業株式会社 | 血液凝固時間に影響を与える物質の定量方法 |
| EP0841566A1 (en) | 1996-11-11 | 1998-05-13 | Pentapharm A.G. | Positive control plasma for lupus anticoagulant |
| DK1493439T3 (da) | 1997-04-02 | 2012-01-30 | Brigham & Womens Hospital | Middel til fastlæggelse af en persons risikoprofil for aterosklerotisk sygdom |
| US6010911A (en) | 1997-04-30 | 2000-01-04 | Medtronic, Inc. | Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique |
| PT947585E (pt) | 1998-03-19 | 2001-11-30 | Instrumentation Lab Spa | Metodo in vitro melhorado, kits e reagentes para a peaquisa de defeitos de coagulacao sanguinea |
| US6027115A (en) * | 1998-03-25 | 2000-02-22 | International Game Technology | Slot machine reels having luminescent display elements |
| US6249855B1 (en) * | 1998-06-02 | 2001-06-19 | Compaq Computer Corporation | Arbiter system for central processing unit having dual dominoed encoders for four instruction issue per machine cycle |
| BR9815975A (pt) | 1998-07-31 | 2001-12-04 | Wallace E Carroll | Método e aparelho para a determinação defatores de terapia anticoagulante |
-
2000
- 2000-02-04 AU AU34833/00A patent/AU774889B2/en not_active Ceased
- 2000-02-04 AT AT00913371T patent/ATE282208T1/de not_active IP Right Cessation
- 2000-02-04 DE DE60015726T patent/DE60015726T2/de not_active Expired - Lifetime
- 2000-02-04 CA CA2362055A patent/CA2362055C/en not_active Expired - Fee Related
- 2000-02-04 WO PCT/US2000/002987 patent/WO2000046603A1/en not_active Ceased
- 2000-02-04 ES ES00913371T patent/ES2231167T3/es not_active Expired - Lifetime
- 2000-02-04 EP EP00913371A patent/EP1147423B1/en not_active Expired - Lifetime
- 2000-02-04 JP JP2000597634A patent/JP4486260B2/ja not_active Expired - Fee Related
-
2004
- 2004-07-02 US US10/884,293 patent/US7211438B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1147423A1 (en) | 2001-10-24 |
| CA2362055A1 (en) | 2000-08-10 |
| WO2000046603A1 (en) | 2000-08-10 |
| JP4486260B2 (ja) | 2010-06-23 |
| US20040248308A1 (en) | 2004-12-09 |
| JP2002541431A (ja) | 2002-12-03 |
| ES2231167T3 (es) | 2005-05-16 |
| AU3483300A (en) | 2000-08-25 |
| AU774889B2 (en) | 2004-07-08 |
| US7211438B2 (en) | 2007-05-01 |
| ATE282208T1 (de) | 2004-11-15 |
| DE60015726D1 (de) | 2004-12-16 |
| EP1147423A4 (en) | 2002-04-17 |
| EP1147423B1 (en) | 2004-11-10 |
| CA2362055C (en) | 2010-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60015726T2 (de) | Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben | |
| DE69615556T2 (de) | Verfahren und apparat zum vorhersagen der präsenz von angeborenen und erworbenen unausgewogenheiten und therapeutischen zuständen | |
| US6564153B2 (en) | Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade | |
| DE69021849T2 (de) | Verfahren zur Bestimmung des Spiegels von exogenen und endogenen Gerinnungsfaktoren und von Protein C. | |
| US6898532B1 (en) | Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample | |
| EP4413591A1 (de) | Computerimplementiertes verfahren und system zur bestimmung von erkrankungen, die sich auf morphologische merkmale und die zytoplasmatische komplexität von blutzellen auswirken | |
| Bahr et al. | Neonatal reference intervals for the complete blood count parameters MicroR and HYPO-He: sensitivity beyond the red cell indices for identifying microcytic and hypochromic disorders | |
| DE10159262B4 (de) | Identifizieren pharmazeutischer Targets | |
| DE69633681T2 (de) | Verfahren zur feststellung von reperfusion nach thrombolytischer therapie | |
| DE60028374T2 (de) | Verfahren und apparatur zum präsentieren von daten von thrombose- und haemostaseassays | |
| DE69931613T2 (de) | Verfahren zum Zählen von Leukozyten und Leukozytenzähler | |
| RU2733077C1 (ru) | Способ диагностики острого коронарного синдрома | |
| Hao et al. | Construction and verification of risk predicting models to evaluate the possibility of hydrocephalus following aneurysmal subarachnoid hemorrhage | |
| DE69906865T2 (de) | Automatisches Diagnosesystem zur Durchführung von Immunoassays und klinisch-chemischen Assays nach einem Reflexalgorithmus | |
| EP2167977B1 (de) | Verfahren zur bestimmung thrombogener mikropartikel | |
| EP1522860A1 (en) | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample | |
| Turhan | New inflammatory markers in diagnosing acute appendicitis | |
| DE102013203839B4 (de) | Verfahren zur Analyse einer Blutprobe und zugehöriges Hämatologie-System | |
| DE102021120512A1 (de) | Bewertungseinheit für ein medizinisches System | |
| Peetz et al. | POCT in der Gerinnungsdiagnostik |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: HEYER, V., DIPL.-PHYS. DR.RER.NAT., PAT.-ANW., 806 |